Abstract:Background Pulmonary arterial hypertension (PAH) is characterized by progressive increase of pulmonary vascular resistance and remodeling that result in right heart hypertrophy and failure. Published studies show that recessive mutations of EIF2AK4 gene (encoding GCN2, General control nonderepressibe 2 kinase) are linked to heritable pulmonary veno-occlusive disease (PVOD) in patients and EIF2AK4 mutations were also found in PAH patients although very rare. However, the role of GCN2 kinase in the pathogenesis of PAH remains unclear. Methods Eif2ak4-/- mice with genetic disruption of the kinase domain and GCN2 kinase inhibitor A-92 were employed in animal models of PH including chronic hypoxia-exposed mice and monocrotaline-challenged rats. Human lung endothelial cells (HLMVECs) were used for mechanistic studies. Endothelium-targeted nanoparticles were employed to deliver plasmid DNA to adult mice to knockout Eif2ak4 or overexpress Endothelin-1 (Edn1) selectively in ECs. Results Here we show that loss of GCN2 induced neither spontaneous PVOD nor PH in Eif2ak4-/- mice but inhibited hypoxia-induced PH evident by reduced right ventricular systolic pressure, right ventricle hypertrophy and pulmonary vascular remodeling. RNA sequencing analysis suggested Edn1 as the downstream target of GCN2. In cultured HLMVECs, GCN2 was phosphorylated and activated in response to hypoxia, mediating hypoxia-induced Edn1 expression via HIF-2α. Restored Edn1 expression in ECs in Gcn2 -deficient mice reversed the reduced phenotype of hypoxia-induced PH. Furthermore, loss of endothelial Eif2ak4 in mice attenuated hypoxia-induced PH. Monocrotaline-induced PH and pulmonary vascular remodeling in rats were inhibited by GCN2 inhibitor A-92 treatment. The clinical relevance of the observation was validated by GCN2 hyperphosphorylation indicative of activation in ECs of pulmonary vascular lesions of PAH patients. Conclusion These studies demonstrate that GCN2 activation by hypoxia mediates pulmonary vascular remodeling and PAH through Edn1. Thus, targeting GCN2 signaling is a promising therapeutic strategy for treatment of PAH in patients without EIF2AK4 loss of function mutations. ### Competing Interest Statement Y.Y.Z is the founder and chief scientific officer of Mountview Therapeutics LLC. This project utilizes technologies subject to the following pending patent PCT/US2019/055787 ?PLGA-PEG nanoparticles and methods of uses? by Zhao, Y.Y. The other authors declare no competing interests. * ECs : endothelial cells CRISPR : Clustered regularly interspaced short repeats, gRNA, guide RNA HLMVECs : Human lung microvascular endothelial cells LV+S : left ventricle+septum MCT : monocrotaline (I)PAH : (idiopathic) pulmonary arterial hypertension PH : pulmonary hypertension PVOD : pulmonary veno-occlusive disease RV : right ventricle; RVSP, right ventricle systolic pressure SMC : smooth muscle cells

GCN2 Regulates ATF3-p38 MAPK Signaling Transduction in Pulmonary Veno-Occlusive Disease

EIF2AK4 Mutation in Pulmonary Veno-Occlusive Disease

Abstract 17370: Activation of Endothelial GCN2 Kinase Contributes to Pulmonary Vascular Remodeling and Pulmonary Arterial Hypertension

GCN2 kinase activation mediates pulmonary vascular remodeling and pulmonary arterial hypertension

Post-translational regulation of PGC-1α modulates fibrotic repair.

Reversal of pulmonary veno-occlusive disease phenotypes by inhibition of the integrated stress response

The Unexpected Role of GCN2 Kinase Activation in Mediating Pulmonary Arterial Hypertension

Differential Expression Profile of microRNAs and Tight Junction in the Lung Tissues of Rat With Mitomycin-C-Induced Pulmonary Veno-Occlusive Disease

Vascular Endothelial Cell-Specific Connective Tissue Growth Factor (CTGF) Is Necessary for Development of Chronic Hypoxia-Induced Pulmonary Hypertension

Mitomycin C induces pulmonary vascular endothelial‐to‐mesenchymal transition and pulmonary veno‐occlusive disease via Smad3‐dependent pathway in rats

Selective deletion of connective tissue growth factor attenuates experimentally-induced pulmonary fibrosis and pulmonary arterial hypertension

O-GlcNAc transferase regulates collagen deposition and fibrosis resolution in idiopathic pulmonary fibrosis

Depletion of Protein Phosphatase 1 Results in Persistent Activation of the Integrated Stress Response and Age-Associated Exacerbation of Pulmonary Veno-Occlusive Disease

Mechanisms underlying age-associated exacerbation of pulmonary veno-occlusive disease

SGK1, a Critical Regulator of Immune Modulation and Fibrosis and a Potential Therapeutic Target in Chronic Graft-Versus-Host Disease

Hyperactivation of ATF4/TGF-β1 signaling contributes to the progressive cardiac fibrosis in Arrhythmogenic cardiomyopathy caused by DSG2 Variant

PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension

Rapid disease progress in a PVOD patient carrying a novel EIF 2 AK 4 mutation: a case report

Lysyl Hydroxylase 3 Increases Collagen Deposition and Promotes Pulmonary Fibrosis by Activating TGFβ1/Smad3 and Wnt/β-catenin Pathways

Abstract 13229: Coiled-Coil Domain-Containing Protein 80 Protects Against Aortic Dissection by Maintaining the Contractile Smooth Muscle Cell Phenotype

GOLM1 Promotes Pulmonary Fibrosis through Upregulation of NEAT1